Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05854563 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cough Capture as a Portal Into the Lung

Study acronym: CC1
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Eligibility criteria expanded, about 24 words
    • Study description expanded, about 100 words
    • Site contact updated
    • Collaborators: 4 to 11
    v4
  2. Notable Primary and study completion dates: Jun 2024 to Jun 2027v3
  3. Notable Enrollment target: 10 to 2000
    • Primary completion date: Feb 1, 2024 to Jun 2024
    • Study completion date: Feb 24, 2024 to Jun 2024
    • Collaborators: 1 to 4
    v2
  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection/risk assessment and diagnostic purposes. However, large macromolecules are not likely suspended nor readily detected in the breath. In particular, genomic DNA in the breath condensate (EBC) is very sparse, and where present, generally highly fragmented, not readily amenable to sequencing based assessments of DNA somatic mutation burden or distribution. Because gDNA (and protein) is challenging to obtain non-invasively from EBC, the study team considered alternative surrogate lower airway specimens. Cough capture is rarely done, and the investigator team is in the process of optimizing its collection. Importantly, the team will be evaluating how much of coughed material is from saliva contamination. Additionally, analyzing material that is target captured by capturing deep lung extracellular vesicles (EVs) using immobilized CCSP/SFTPC antibodies targeting EVs from distal bronchiole Club and alveolar type 2 cells could circumvent the mouth contamination problem, leaving a non-invasive portal to the deep lung suitable for large molecules, and in turn suitable for myriad epidemiologic and clinical applications. The investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL/bronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg/Maslov labs. Finally, the investigator team will (Aim 3) test all airway specimens (cough, mouthwash and BAL) for lung surrogacy of cough, using proteins known to be specific for lung, as opposed to oral cavity/saliva, in the Sidoli/proteomics core. The investigator team envisions that the translational impact of non-invasively obtained DNA or protein markers could allow for more rapid acute clinical diagnoses, and facilitate precision prevention and/or early detection of many acute and chronic respiratory disorders, including lung cancer, asthma and COPD, acute and chronic infectious diseases, and indeed systemic disorders of inflammation and metabolism.
Trial Details
NCT Number NCT05854563
Lead Sponsor Albert Einstein College of Medicine
Collaborators: National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS), Evaluate Diagnostics, James J. Peters Veterans Affairs Medical Center, Touro University, Hackensack Meridian Health, The Scripps Research Institute, Weill Medical College of Cornell University, Cold Spring Harbor Laboratory
Conditions
(from sponsor)
Lung Diseases, Lung Cancer, Lung Diseases, Obstructive, Lung Diseases, Interstitial, Lung Inflammation
Related terms Lung Diseases, Lung Diseases, Interstitial, Lung Diseases, Obstructive, Lung Neoplasms, Pneumonia
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov